Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of small-molecule therapies for diseases with significant unmet medical need, primarily in metabolic dysfunction–associated steatohepatitis (MASH, formerly NASH) and oncology. The company’s core value is driven by its proprietary drug discovery expertise targeting nuclear receptors, transcription factors, and epigenetic modulation, areas with established biological validation but limited therapeutic options.
The company was founded in 2012 by scientists from INSERM (the French National Institute of Health and Medical Research) and has evolved from a discovery-focused biotech into a late-stage clinical developer. Inventiva’s lead asset, lanifibranor, is a pan-PPAR agonist designed to address both fibrosis and metabolic dysfunction in MASH, positioning the company uniquely among peers pursuing single-pathway approaches. Inventiva is publicly listed on Euronext Paris and NASDAQ under the ticker IVA.
Business Operations
Inventiva operates primarily through two core research and development segments: MASH/metabolic diseases and oncology. The company generates value through internal drug discovery, clinical development, and strategic collaborations, rather than through product sales, as it does not yet have approved commercial therapies. The majority of expenditures are related to clinical trials, regulatory activities, and research operations.
The company’s operations are centered on its proprietary chemical library and drug discovery platforms, which support both wholly owned programs and partnered assets. Inventiva has historically entered into research and licensing collaborations with large pharmaceutical companies, generating milestone and research payments. Its most advanced program, lanifibranor, is wholly owned and has progressed into late-stage clinical development, representing the primary driver of investor interest and corporate focus.
Strategic Position & Investments
Inventiva’s strategy is centered on advancing lanifibranor toward potential regulatory approval in MASH, a large and competitive market with limited approved therapies. The company has invested heavily in late-stage clinical trials and regulatory engagement to position lanifibranor as a differentiated therapy addressing inflammation, fibrosis, and metabolic dysfunction simultaneously.
Beyond its lead program, Inventiva maintains a pipeline of earlier-stage assets in oncology, including compounds targeting transcriptional and epigenetic regulators. The company has also leveraged strategic partnerships and out-licensing agreements to monetize non-core assets while retaining focus on its highest-value programs. No major acquisitions have been publicly disclosed; growth has primarily been organic and pipeline-driven.
Geographic Footprint
Inventiva is headquartered in France, with its principal offices and research facilities located in Dijon. The company’s operational footprint is primarily European, but its clinical development activities are global, including trial sites in North America, Europe, and other international regions.
As a dual-listed company on European and U.S. capital markets, Inventiva maintains a strong international investor presence and conducts regulatory interactions with both European and U.S. authorities. While it does not have large-scale commercial infrastructure, its global clinical trial network provides broad international exposure and operational reach.
Leadership & Governance
Inventiva was founded by experienced scientists with deep expertise in nuclear receptor biology, and the company continues to be led by its co-founders, reflecting continuity in scientific and strategic vision. Leadership emphasizes science-driven decision-making, disciplined capital allocation, and a focused approach to late-stage asset development.
Key executives include:
- Frédéric Cren – Chairman of the Board & Chief Executive Officer
- Pierre Broqua – Chief Scientific Officer & Co‑founder
Public disclosures identify additional executive and senior management roles; however, detailed confirmation of specific titles beyond the above individuals is inconclusive based on available public sources.